ABIVAX (EPA:ABVX) | Finanzwire

Basculer en Français

10656	Companies
226942	Keywords
155382	Articles
120170	Press releases

Home
Companies
ABIVAX

BRIEF

published on 06/29/2026 at 22:52, 8 hours 56 minutes ago

ABIVAX: Promising results from the ABTECT trial for ulcerative colitis

Security Abivax Obefazimod Ulcerative Colitis Clinical Trial
BRIEF

published on 06/29/2026 at 22:10, 9 hours 38 minutes ago

ABIVAX: Positive results for obefazimod in refractory ulcerative colitis

Security Abivax Obefazimod Clinical Trial Refractory Ulcerative Colitis
BRIEF

published on 06/29/2026 at 22:10, 9 hours 39 minutes ago

Abivax Announces Positive Phase 3 Results for Obefazimod in Ulcerative Colitis

Obefazimod Ulcerative Colitis Phase 3 Results Safety Profile Clinical Remission
PRESS RELEASE

published on 06/29/2026 at 22:05, 9 hours 44 minutes ago

Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory UC Patients and Strengthening the Phase 3 Maintenance Safety Database
Abivax reports positive ABTECT Maintenance Part 2 results for obefazimod in refractory UC patients, demonstrating meaningful clinical benefit and strengthening safety database

Abivax Obefazimod Clinical Benefit UC Patients Safety Database
BRIEF

published on 06/17/2026 at 18:05, 12 days 13 hours ago

ABIVAX: Distribution of Shares and Voting Rights as of May 31, 2026

Voting Rights Shares Euronext AMF Abivax
BRIEF

published on 06/02/2026 at 10:16, 27 days 21 hours ago

Bank of America Corporation exceeds 5% of ABIVAX's capital

Actions Abivax Financial Market Crossing Thresholds Bank Of America
BRIEF

published on 06/01/2026 at 22:10, 28 days 9 hours ago

Abivax Announces Phase 3 Trial Results for Ulcerative Colitis Treatment

Abivax Obefazimod Ulcerative Colitis Clinical Trial Phase 3 Results
BRIEF

published on 06/01/2026 at 22:10, 28 days 9 hours ago

Promising results of obefazimod in the treatment of ulcerative colitis

Abivax Obefazimod Ulcerative Colitis Clinical Trial FDA Authorization
PRESS RELEASE

published on 06/01/2026 at 22:05, 28 days 9 hours ago

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis
Abivax announces positive Phase 3 ABTECT maintenance trial results for obefazimod in ulcerative colitis, demonstrating significant efficacy and safety profile. Plans NDA submission to FDA in late 2026

FDA Abivax Obefazimod Ulcerative Colitis Phase 3
BRIEF

published on 05/29/2026 at 18:05, 1 month ago

ABIVAX: Update on capital and voting rights

Share Capital Voting Rights Actions AMF Abivax

Accesswire

Published on 06/30/2026 at 05:30, 2 hours 19 minutes ago

Nano One Renews At-The-Market Equity Program
Published on 06/30/2026 at 02:00, 5 hours 49 minutes ago

MedMira Reports Third Quarter Results FY2026
Published on 06/30/2026 at 00:05, 7 hours 44 minutes ago

American Critical Minerals Announces Completion of Warrant Exercise Incentive Program
Published on 06/29/2026 at 23:46, 8 hours 3 minutes ago

1933 Industries Reports Third Quarter 2026 Financial Results
Published on 06/29/2026 at 22:01, 9 hours 48 minutes ago

AIP Realty Trust Announces Voting Results of Annual General and Special Meeting of Unitholders

View all ACCESSWIRE

EQS Group

Published on 06/30/2026 at 07:30, 18 minutes ago

REINET INVESTMENTS S.C.A. SHARE BUYBACK PROGRAMME – UPDATE 30 JUNE 2026
Published on 06/30/2026 at 07:30, 18 minutes ago

Mutares portfolio company Amaneos completes acquisition of European Automotive Lighting Business from Magna as strategic add-on for LMS
Published on 06/30/2026 at 07:30, 18 minutes ago

Just – Evotec Biologics Launches J.TRAIN to Deliver Turnkey Continuous Manufacturing for Biologics
Published on 06/30/2026 at 07:13, 35 minutes ago

African Guarantee Fund appoints Mr. Constant N’ZI as Group Chief Executive Officer
Published on 06/30/2026 at 07:05, 44 minutes ago

Infracore SA communicates the decision of the Swiss Takeover Board

Les Echos

Published on 06/30/2026 at 07:30, 19 minutes ago

Gimv sells its stake in AlpenBlu Clinics (formerly Les Psy Réunis), a Swiss provider of outpatient mental healthcare, to Impact Healthcare.
Published on 06/30/2026 at 07:30, 19 minutes ago

Acquisition of Harwanne Capital Management
Published on 06/30/2026 at 07:00, 49 minutes ago

bioMérieux submits 510(k) to U.S. FDA for the latest versions of the BIOFIRE® FILMARRAY® Gastrointestinal Panels to enhance detection of gastrointestinal pathogens
Published on 06/29/2026 at 18:30, 13 hours 19 minutes ago

Accor and H World Group expand long-term partnership across direct booking and loyalty platforms
Published on 06/29/2026 at 17:45, 14 hours 4 minutes ago

Successful issue of a € 1.5 billion bond

View all LES ECHOS COMFI WIRE